Skip to search boxSkip to navigationSkip to main content

Lymph node metastases and prognosis in patients with stage IA2 cervical cancer

  • S. L. Buckley(corresponding author)
    ,
  • D. M. Tritz
    ,
  • L. Van Le
    ,
  • ,
  • B. U. Sevin
    ,
  • F. R. Ueland
*Corresponding author for this work
  • American Cancer Society
    ,
  • University of Kentucky
    ,
  • University of North Carolina at Chapel Hill
    ,
  • Carolinas Medical Center
    ,
  • University of Miami
Scholary Output:
Contribution to journal
Article
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Ninety-four patients with squamous cell carcinoma invading the cervical stroma to a depth of >3.0-5.0 mm with 7 mm or less in horizontal spread (FIGO Stage IA2) were evaluated. Depth and lateral extent of stromal invasion were verified using an ocular micrometer. Cell type and lymph vascular space invasion (LVSI) were recorded in each case. Patients were treated primarily by radical hysterectomy with pelvic lymphadenectomy, and those with lymph node metastases were offered postoperative radiation. Following treatment, patients were seen at 3-month intervals for 2 years, and every 6 months thereafter. The mean duration of follow-up was 6.9 years (range 0.4-23.5 years). Seven of 94 patients (7.4%) had lymph node metastases. Five patients had 1 positive node, 1 patient had 2 positive nodes, and 1 patient had 3 positive nodes. Five patients developed recurrent cancer and 4 died of disease. LVSI was present in 31 cases (33%). Tumor recurrence was significantly increased in patients with positive LVSI (9.7% vs 3.2%). The 5- year survival rate of patients with LVSI was 89% vs 98% in patients without this finding (P = 0.058). The 5-year survival rate of all Stage IA2 cervical cancer patients was 95%. Patients with Stage IA2 cervical cancer have a significant risk of lymph node metastases and should be treated by radical hysterectomy with pelvic lymphadenectomy. LVSI is an important prognostic variable in these patients and should be recorded in all cases.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 4-9 (6 pages)

Journal (Volume, Issue Number)

Gynecologic Oncology (Volume 63, Issue 1)

Publication milestones

  • Published - 10/1996

Publication status

Published - 10/1996

ISSN

0090-8258

Publication IDs

  • Scopus: 0030272531
  • PubMed: 8898159

Publication metrics

Metrics

Scopus
citations
Fractional count
1
Fractional count
0.08
Fractional count
12
Fractional count
0.92
Fractional count
1
Fractional count
1
SciVal
citations
66
SciVal
FWCI
2.16
SciVal
Author count
13
SciVal
Paper percentile
91
SciVal
Top percentile
10

PlumX, opens in new tab

Captures
21
Citation count
85